Johnson & Johnson reports third-quarter results on Tuesday
Analysts expect revenue of $25.58 billion and EPS of $2.59 before the market opens
Johnson & Johnson is scheduled to release its third-quarter financial results on Tuesday, 13 October 2026, before the market opens. The date was confirmed by the company.
The consensus estimate projects earnings of 2.59 USD per share for the third quarter of 2026 on revenue of 25.58 billion USD. In a separate estimate compiled by Guggenheim ahead of the report, third-quarter revenue was projected at 25.37 billion USD and earnings per share at 2.69 USD. Across the last four quarters, the company topped consensus earnings estimates three times by up to 0.9% and missed once by 0.1%.
Johnson & Johnson: estimated vs. reported EPS
Per share, in USD. Oldest quarter first.
Source: Finnhub
Pipeline updates and corporate developments
Ahead of the report, the company announced several clinical trial developments. On 21 September 2026, Johnson & Johnson reported positive topline Phase 3 results for Caplyta in treating manic episodes in adults with bipolar I disorder. On 23 September 2026, Phase 3 trial data showed Tecvayli combined with Darzalex Faspro cut multiple myeloma progression risk by 90%. On 25 September 2026, Tremfya met primary and key secondary endpoints in a Phase 4 study for axial psoriatic arthritis, while partnered depression candidate JNJ-5120/PIPE-307 with Contineum Therapeutics missed its primary endpoint in a Phase 2 trial. On 29 September 2026, the company shared two-year Phase 2/3 data for IMAAVY in generalized myasthenia gravis, followed on 2 October 2026 by two-year Phase 3 data showing sustained skin clearance for oral peptide Icotyde in plaque psoriasis.
On 12 September 2026, Investing.com reported that Apollo Global Management entered discussions to acquire Johnson & Johnson's DePuy Synthes orthopedics unit at an estimated valuation of 20 billion USD. On 17 September 2026, Chief Financial Officer Joseph Wolk stated that the upper range of expected impact from product loss of exclusivity facing the company is 4.5 billion USD, according to a transcript published by Seeking Alpha. The company previously declared and distributed a quarterly cash dividend of 1.34 USD per share for the third quarter.
Share prices can rise and fall. Past performance does not guarantee future results. This article is news, not investment advice.
Newsletter
Markets in your inbox, weekly
LATAM-focused analysis, investing ideas, and the week in finance.
Keep reading
